Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background/aims The diagnosis of cholangiocarcinoma in primary sclerosing cholangitis (PSC), even with the use of current imaging techniques and brush cytology, is difficult and particularly important in patients being assessed for liver transplantation. This study investigated the accuracy of serum levels of a combination of the tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) in the diagnosis of cholangiocarcinoma in patients with PSC.Methods Seventy-four patients with PSC were studied. Fifteen patients had tumors (11 occult on imaging), 22 had severe PSC that necessitated transplantation (with explanted liver known to be free of tumor), and 37 patients had stable PSC.Results An index of the two serum tumor markers [using the formula CA19-9 + (CEA x 40)] gave an accuracy of 86% in diagnosis of cholangiocarcinoma, with 10 of the 15 cases of cholangiocarcinoma having an increased value compared with none in a group of 22 comparable cases with no tumor. In addition, 6 of the 11 patients with occult tumors had abnormal values. Ultrasonography, computerized tomographic scanning, and endoscopic retrograde cholangiopancreatography were poor predictors of the presence of tumor.Conclusions A combination of serum tumor markers will identify most occult tumors and will improve selection of appropriate cases for orthotopic liver transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They are of limited diagnostic sensitivity and specificity, either alone or in combination.124,126,128,301,302”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [301]
Citations
Cites
Chapman, R. W., Arborgh, B. A., Rhodes, J. M., Summerfield, J. A., Dick, R., Scheuer, P. J., & Sherlock, S. (1980) · Gut · doi:10.1136/gut.21.10.870 · Cited by 732
Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis
Wiesner, R. H., Grambsch, P. M., Dickson, R. E., Ludwig, J., Maccarty, R. L., Hunter, E. B., Fleming, T. R., Fisher, L. D., Beaver, S. J., & Larusso, N. F. (1989) · Hepatology · doi:10.1002/hep.1840100406 · Cited by 643
(1990) · PubMed · Cited by 579
Natural history and prognostic variables in primary sclerosing cholangitis
Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., & Williams, R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90673-9 · Cited by 468
Self-citationLiver Transplantation for Malignant Disease: Results in 93 Consecutive Patients
OʼGRADY, J. G., POLSON, R. J., ROLLES, K., CALNE, R. Y., & WILLIAMS, R. (1988) · Annals of Surgery · doi:10.1097/00000658-198804000-00002 · Cited by 446
Self-citationCholangiocarcinoma Complicating Primary Sclerosing Cholangitis
ROSEN, C. B., NAGORNEY, D. M., WIESNER, R. H., COFFEY, R. J., & LARUSSO, N. F. (1991) · Annals of Surgery · doi:10.1097/00000658-199101000-00004 · Cited by 391
Primary sclerosing cholangitis: Refinement and validation of survival models
Dickson, E. R., Murtaugh, P. A., Wiesner, R. H., Grambsch, P. M., Fleming, T. R., Ludwig, J., LaRusso, N. F., Malinchoc, M., Chapman, R. W., Kaplan, M. M., et al. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91449-e · Cited by 270
Self-citationOrthotopic Liver Transplantation for Primary Sclerosing Cholangitis
MARSH, J. W., IWATSUKI, S., MAKOWKA, L., ESQUIVEL, C. O., GORDON, R. D., TODO, S., TZAKIS, A., MILLER, C., THIEL, D. V., & STARZL, T. E. (1988) · Annals of Surgery · doi:10.1097/00000658-198801000-00005 · Cited by 253
Steinberg, W. M., Gelfand, R., Anderson, K. K., Glenn, J., Kurtzman, S. H., Sindelar, W. F., & Toskes, P. P. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90930-3 · Cited by 215
NICHOLS, J. C., GORES, G. J., LARUSSO, N. F., WIESNER, R. H., NAGORNEY, D. M., & RITTS, R. E. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60696-x · Cited by 214
Research works printed but not linked: 3
- Steinberg, 1990, The clinical utility of the CA19-9 tumour associated antigen, Am J Gastroenterol, 85, 350
- Safi, 1986, Ca19-9 and pancreatic adenocarcinoma, Cancer, 57, 779, 10.1002/1097-0142(19860215)57:4<779::AID-CNCR2820570417>3.0.CO;2-C · doi:10.1002/1097-0142(19860215)57:4<779::aid-cncr2820570417>3.0.co;2-c
- Ramage, 1989, Are serum values of tumour markers useful clinically in predicting the presence of pancreatic malignancy (abstr)?, Gut, 30, A1507
Cited by
Khan, S. A., Thomas, H. C., Davidson, B. R., & Taylor-Robinson, S. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67530-7 · Cited by 1,042
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
de Groen, P. C., Gores, G. J., LaRusso, N. F., Gunderson, L. L., & Nagorney, D. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411807 · Cited by 955
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
Khan, S. A., Davidson, B. R., Goldin, R., Pereira, S. P., Rosenberg, W. M. C., Taylor-Robinson, S. D., Thillainayagam, A. V., Thomas, H. C., Thursz, M. R., & Wasan, H. (2002) · Gut · doi:10.1136/gut.51.suppl_6.vi1 · Cited by 648
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
Metadata
- Authors
- Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R.
- Affiliations
- King's College Hospital (GB)
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1995-03
- Volume
- 108
- Issue
- 3
- Pages
- 865-869
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2129563967
- Cited by
- 279
- References
- 28
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 5 · 2021: 6 · 2019: 5 · 2018: 5 · 2017: 8 · 2016: 9 · 2015: 9 · 2014: 8 · 2013: 5 · 2012: 13
- FWCI
- 10.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- cholangiocarcinoma, primary sclerosing cholangitis, serum tumor markers, carcinoembryonic antigen, CA19-9, occult malignancy, liver transplantation, tumor diagnosis, diagnostic accuracy
- MeSH terms
- Adult, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Carcinoembryonic Antigen, Cholangiopancreatography, Endoscopic Retrograde, Female, Humans, Male, Middle Aged, Sensitivity and Specificity, Biomarkers, Tumor, Ultrasonography, Cholangitis, Sclerosing, Antigens, Tumor-Associated, Carbohydrate, Cholangiocarcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1016/0016-5085(95)90462-x
- The paper
- Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R. (1995). Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. https://doi.org/10.1016/0016-5085(95)90462-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.